NCT06900335View on ClinicalTrials.gov

Functional Connectome in Prader-Willi Syndrome: Neuroimaging and AI to Assess Therapeutic Impact

CompletedOBSERVATIONAL
Enrollment

101

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 15, 2025

Study Completion Date

March 15, 2025

Conditions
Prader Willi SyndromeHyperphagiaBehavior Disorders
Interventions
DRUG

GH treatment (Somatropin)

Treatment with Somatropin (recombinant GH), with doses starting from 0.2 mg/day and adjusted as necessary.

BEHAVIORAL

Eating

Allowing patients to break fasting.

Trial Locations (1)

08202

Consorci Corporació Sanitària Parc Taulí, Sabadell

Sponsors
All Listed Sponsors
lead

Corporacion Parc Tauli

OTHER